Conclusions: Our data indicated that treatment with CpG-ODN inhibited the HepG2 cells-mediated Jurkat cell apoptosis by modulating the Fas/FasL pathway. Apparently, CpG-ODN treatment may be a potential therapeutic reagent for HCC.
Introduction
Tumors escape immune surveillance through multiple mechanisms. For example, tumors can produce inhibitory factors, such as transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF), leading to the reduced dendritic cell activation and impaired tumor-specific T cell immunity [1] . Tumor cells can up-regulate some of the functional surface molecules, including FasL, which can actively induce the apoptosis of the Fas-expressing activated T lymphocytes, while others can down-regulate the expression of other molecules, such as MHC class I and Fas [2, 3] . Although the mechanisms by which tumor cells evade immune surveillance are not well understood, the selective induction of tumor cell apoptosis has been thought to be a valuable strategy for tumor therapy. CpG-ODN can function as a Th-1 adjuvant [4] and is able to activate dendritic cells [5] . Accordingly, CpG-ODN has been used as an adjuvant for the induction of anti-tumor immune responses [6] [7] [8] .
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide, particularly in China. Accumulating evidences have suggested that several mechanisms contribute to the carcinogenesis of HCC [9, 10] . The relative resistance to apoptosis triggering and the strong proliferation in HCC cells have been thought as predominant factors contributing to the development of HCC [11] . Recently, high levels of FasL have been found in HCC tumor cells [12] . Given that This study aimed at exploring the potential effect of CpG-OND treatment on the HepG2-induced Jurkat cell apoptosis. We found that treatment with CpG-ODN down-regulated the expression of FasL in HepG2 cells and Fas in Jurkat cells, and inhibited the HepG2-mediated Jurkat cell apoptosis in vitro. We discussed the implication of our findings.
Materials & methods

Reagents
The CpG-ODN-M362 [13] used in the experiment was synthesized by Invitrogen (Invitrogen Inc, Shanghai, China). Oligonucleotides were dissolved in TE-buffer (pH 8.0) containing 10 mM Tris-HCl and 1 mM EDTA at a concentration of 100 μM, which were then aliquoted and stored at -20°C until use. RPMI-1640 medium was obtained from Invitrogen Inc. (Carlsbad, CA, USA). Fetal bovine serum (FBS) was purchased from GIBCO BRL (Grand Island, NY, USA). Monoclonal antibody against human FasL, NOK-2, was purchased from BD Pharmingen (San Diego, CA, USA).
Cell culture
Human hepatocellular carcinoma cell line, HepG2 and lymphoma cell line, Jurkat were maintained in our laboratory and cultured in RPMI-1640 medium supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin in 25 cm 2 polystyrene flasks at 37°C in a humidified atmosphere of 5% CO 2 incubator. Routine passage was carried out every 2 or 3 days. In addition, the unmanipulated Jurkat cells or the CpG-ODN-treated Jurkat cells were harvested after coculture with unmanipulated HepG2 or the CpG-ODNtreated HepG2 cells. The cells were stained with PEanti-activated caspase-3 using the PE-conjugated active caspase-3 apoptosis kit (BD Pharmingen), and the activation of capsase-3 was determined by flow cytometry analysis.
Flow cytometry analysis
qRT-PCR
Total RNA was extracted from the unmanipulated and CpG-ODN-treated Jurkat cells using Trizol reagent, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA), and reversely transcribed into cDNA using oligo (dT) 12-18 and ReverTraAce-α™ (Toyobo. Co., Japan), resepctively. The relative levels of Fas mRNA transcripts to control GAPDH were determined by quantitative real-time PCR using the SYBR Green One-Step kit and the specific primers on a LightCycler™ (Roche Diagnostics, Mannheim, Germany). The sequences of the primers were synthesized by Invitrogen (Invitrogen Inc, Shanghai, China) and are presented in Table 1 . The PCR reactions containing 0.4 μM FasL primers, 2.5 μM MgCl 2 , 1 × SYBR Green master mix, and 1 μL cDNA were performed in duplicate at 95°C for 5 min for denaturation and subjected to 40 cycles of 95°C for 15 s, 57°C for 5 s, 72°C for 10 s and then 78°C for 5 s. Data were analyzed using LightCycler analysis software. The individual PCR efficiencies were determined using LinRegPCR [14] , and the mRNA expressions (rER values) for Fas and FasL were calculated by the Gene Expression's C (T) Difference (GED) method [15] .
Statistical analysis
Data were expressed as means ± S.E.M. Statistical significance was assessed using either Student's t-test or oneway ANOVA followed by post hoc Dunnett, SNK test. A value of p < 0.05 was considered significantly different. 
Results
CpG-ODN downregulated the expression of FasL in HepG2 cells in a dose-and time-dependent manner
Effect of CpG-ODN on the Fas expression in Jurkat cells
Next, we tested whether treatment with CpG-ODN could modulate the expression of Fas in Jurkat cells. Jurkat cells were treated with 1 μM CpG-ODN for 24 h. The cells were harvested and the relative levels of Fas mRNA transcripts to control GAPDH were determined by quantitative RT-PCR (Figure 2A) . Clearly, the relative levels of Fas mRNA transcripts in the CpG-ODN-treated Jurkat cells were reduced to 65%, as compared with that of unmanipulated controls. Furthermore, the expression of Fas in Jurkat cells was also examined by flow cytometry analysis. The frequency of Fas-expressing Jurkat cells was significantly reduced from 54% ± 2% to 35% ± 1% ( Figure 2B 
Caspase-3 activity analysis
The activation of caspase-3 is crucial for the intrinsic and extrinsic apoptotic pathways. Accordingly, we selectively examined the activity of caspase-3, a downstream factor of the Fas-FasL pathway. As shown in Figure 4 , the levels of activated caspase-3 were significantly reduced in the CpG-ODN-treated Jurkat cells (28.20 ± 0.18%), as compared to unmanipulated Jurkat cells (45.15 ± 0.13%). These data suggested that the CpG-ODN reduced HepG2-induced Jurkat cell death through the caspase-3-dependent apoptotic pathway.
Discussion
The up-regulated expression of FasL has been found in various types of tumors, including melanoma, lymphoma, gastric carcinoma, and breast carcinoma [16] . It has been reported that high levels of FasL expression are associated with the presence of tumor-infiltrating lymphocytes (TIL), leading to high susceptibility of activated T cells in tumor tissues to apoptosis triggers due to high levels of Fas expression by activated T cells [17] . Indeed, engagement of Fas by the FasL can promote the formation of death-inducing signaling complex, resulting in activated T cell apoptosis. This may partially contribute to tumor cells escaping from immune surveillance and leading to tumor progression.
Due to the important role of Fas in the tumor progression and metastasis, the Fas-mediated apoptosis might be a target for cancer therapy. Notably, the apoptotic cascade is a sequential process of many events that can be regulated at different stages. Several agents have been found to directly or indirectly inhibit cellular apoptosis. The arsenic trioxide and tumor necrosis factorrelated apoptosis-inducing ligand receptor (TRAIL) can modulate the intrinsic and extrinsic pathways, respectively [18] . The caspase activators can regulate the common pathway, and ONY-015 can regulate modulators of the apoptosis pathways [19] . CpG-ODN can activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-B) and activated protein 1 through the Tolllike receptor (TLR) sigaling pathway [20] , and has been thought to act as a potent adjuvant for inducing Th1 response. The NF-B can regulate the expression of the FasL gene, exhibiting both anti-apoptotic and pro-apoptotic functions [19] . In this study, we examined the effects of CpG-ODN treatment on the HepG2 cellinduced Jurkat cell apoptosis. We found that CpG-ODN inhibited the expression of FasL in HepG2 in a doseand time-dependent manner ( Figure 1 ). Treatment with CpG-ODN at 1 μM for 24 h greatly inhibited the expression of FasL in HepG2 cells in vitro. Furthermore, we found that treatment with CpG-ODN effectively down-regulated the expression of Fas in human Jurkat cells (Figure 2 ). Jurkat cells are derived from human T lymphocyte leukemia cells, mimic the activated T lymphocyte cells, and have been widely used as experimental models to study the functions of T cells [21] . In addition, co-culturing the unmanipulated HepG2 cells with Jurkat cells triggered a high frequency of Jurkat cells undergoing apoptosis, which was effectively abrogated by pre-treatment of either HepG2 or Jurkat cells with anti-FasL antibody. These data indicated that HepG2 cells induced Jurkat cell apoptosis via the Fas/ FasL pathway. More importantly, pre-treatment of Jurkat cells or HepG2 cells with CpG-ODN efficiently inhibited the HepG2-mediated Jurkat cell apoptosis (Figure 3 ) and the caspase activation in Jurkat cells ( Figure  4 ). CpG-ODN can suppress apoptosis of macrophages via TLR9 through PKB/Akt/FOXO pathway [22] , since macrophages and T cells play an important role in antitumor immune, our study showed CpG-ODN suppresses apoptosis through FasL/Fas pathway, maybe PKB/Akt/FOXO is another way in anti-apoptosis anticancer therapeutic strategies of CpG-ODN.
Currently, treatment of HCC relies on surgery, conventional chemotherapy, and radiation therapy at clinic. Other therapeutic strategies, such as an antibody targeting the specific molecules, are currently in trials. DNAbased drugs, such as CpG-ODN and antisense ODN, are regarded as a new alternative therapy for the brain tumors [23] . The regulation of the complex signaling pathways in tumors has been a new strategy for the rational design of anticancer strategies. Escaping from immune surveillance and being resistant to apoptosis triggers play an important role in the progression and metastasis of tumors. Our results indicated that CpG-ODN down-regulated the FasL expression in HepG2 
